The abnormal expression of MARCH8 leads to the downregulation of several immunomodulatory receptors, such as MHC I, HLA 2.1, and TNF-related apoptosis,28,29 indicating its potential as a promising target in cancer immunotherapy. This evidence concerns the gene MARCHF8 and cancer.